Clinical trials: no Conditions
Solid Tumors
Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)
- Trial name
- NCT00687934
- Testing
- STA-9090
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Synta Pharmaceuticals Corp.
Chronic Heart Failure
Bioequivalence Study to Compare Sacubitril and Valsartan Tablets (97mg/103mg) Versus Entresto® (Sacubitril and Valsartan) Tablets (97 mg/103 mg)
An open label, balanced, randomized, single dose, two treatment, two sequence, four period, full-replicate, oral bioequivalence Study of Sacubitril and Valsartan 97 mg/103 mg Tablets of HUMANİS SAĞLIK ANONİM ŞİRKETİ Ç.O.S.B.…
- Trial name
- NCT06922253
- Testing
- Sacubitril and Valsartan-Test product, Sacubitril and Valsartan-Reference product
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Non 24 Hour Sleep Wake Disorder
Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception
The purpose of this study is to evaluate the safety of a one year open-label treatment of tasimelteon in male and female subjects with Non-24-Hour Sleep-Wake Disorder.
- Trial name
- NCT01218789
- Testing
- tasimelteon
- Where
- 7 sites in France
- Volunteers
- 140 people
- Sponsor
- Vanda Pharmaceuticals
No Specific Medical Conditions or Disease States
Non-invasive Monitoring: Impact on Patient Management and Outcomes
Enhancing patient monitoring in SNFs and ALFs is crucial due to challenges in recognizing deteriorating health. Gaps in vital sign checks lead to missed indicators and adverse outcomes.
- Trial name
- NCT06270953
- Testing
- Dozee Pro NX
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Turtle Shell Technologies Pvt. Ltd.
Solid Tumors
Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors
The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry and pharmacokinetics of I-131-CLR1404.
- Trial name
- NCT00925275
- Testing
- I-131-CLR1404
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Cellectar, Inc
Retinitis Pigmentosa, Retinitis
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
The purpose of the study is to evaluate the safety and efficacy of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (MCO-010).
- Conditions
- Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases
- Trial name
- RESTORE (NCT04945772)
- Testing
- Gene Therapy Product-MCO-010
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 27 people
- Sponsor
- Nanoscope Therapeutics Inc.
PTSD
Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study that will investigate the efficacy and safety of two doses of TNX-102 SL -a sublingual formulation of cyclobenzaprine.
- Trial name
- AtEase (NCT02277704)
- Testing
- TNX-102 SL
- Where
- 23 sites in United States
- Volunteers
- 245 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Emergency Department Triage
PREMEDICAL is a Clinical Investigation Aiming to Create a Data Basis That Can be Used to Enrich Information Collected in the Course of the Classic Patient Journey. Patients in the Emergency Department Will be Asked to Answer Patient-related and Symptom-oriented Questions. Minimum Age is 18 Years
The goal of this clinical investigation is to create a new type of data basis that can be used to enrich information collected in the course of the classic patient journey, such as medical history forms and discharge letters.
- Trial name
- NCT06933550
- Where
- Austria
- Volunteers
- 351 people
- Sponsor
- XUND Solutions GmbH
Hepatitis C, Chronic
A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)
SCH 900518 is a potent oral inhibitor of HCV NS3 protease which disrupts hepatitis C virus (HCV) polyprotein processing. SCH 900518, when added to the current standard of care (SOC), peginterferon-alfa plus ribavirin, would…
- Trial name
- NEXT-1 (NCT00797745)
- Testing
- peginterferon alfa 2b, ribavirin, SCH 900518
- Volunteers
- 111 people
- Sponsor
- Merck Sharp & Dohme LLC
Critical Limb Ischemia
Percutaneous Deep Vein Arterialization Post-Market Study
The objective of this post-market study is to evaluate the safety and effectiveness of the LimFlow System in creating a below-the-knee arterio-venous fistula for venous arterialization in subjects with critical limb ischemia.
- Trial name
- PROMISE UK (NCT03807661)
- Testing
- Percutaneous deep vein arterialization, LimFlow System
- Where
- 6 sites in United Kingdom
- Volunteers
- 28 people
- Sponsor
- LimFlow SA
Healthy
ClearView Predicate Comparison Testing
This study serves as a comparison study between the EPIC ClearView and a predicate device.
- Trial name
- NCT01573559
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Healthy
Bioequivalence Study of Fluoxetine HCL 40 mg Capsules Under Fasting Conditions
The objective of this study is to compare the relative bioavailability of fluoxetine HCL 40 mg capsules (by Ranbaxy Laboratories Limited) with that of PROZAC® 40 mg capsules (by Dista Products Company) following a single oral…
- Trial name
- NCT00778024
- Testing
- fluoxetine HCL 40 mg capsules
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Ranbaxy Laboratories Limited
No Condition, Healthy Individuals, No Conditions, Aged 20-64
Evaluating the Hemodynamic Performance of the VenAir Sequential Compression System
The goal of this clinical trial is to learn an Intermittent Pneumatic Compression Device (IPCD), VenAir, effectiveness in healthy adults. The main questions this research aims to answer are: 1.
- Trial name
- NCT07287007
- Testing
- VenAir, SCD700
- Where
- Taiwan
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Wellell Inc. Taiwan
No Specific Conditions Are Being Examined
Comparison Study for Hemodynamic Parameters Generated by Vitalstream Relative to Appropriate Gold Standard References in Different Clinical Settings, (OR, EP Lab Etc.).
The goal of the proposed study is to test the capability of the Vitalstream monitor's continuous blood pressure tracking ability against Gold Standard.
- Trial name
- NCT07775469
- Testing
- Vitalstream
- Volunteers
- 60 people
- Sponsor
- CareTaker Medical LLC
Diarrhea, Infantile
Preventing Antibiotic-Associated DiarRhea Using Erceflora
To determine the effectiveness of the pre-biotic Bacillus clausii in preventing antibiotic associated diarrhea among hospitalized immunocompetent Filipino children.
- Trial name
- PADRE (NCT00447161)
- Testing
- Bacillus Clausii Multi ATB Resist
- Where
- Philippines
- Volunteers
- 323 people
- Sponsor
- Sanofi
Hepatitis C, Chronic
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of a 4-drug regimen with GS-9451 and Tegobuvir and 24 weeks of a 3-drug regimen of GS-9451 without Tegobuvir, all with Peginterferon Alfa-2a (Pegasys®)…
- Trial name
- NCT01271790
- Testing
- Tegobuvir (GS-9190), GS-9451, Pegasys®
- Where
- 144 sites in United States, Austria and 6 more
- Volunteers
- 245 people
- Sponsor
- Gilead Sciences
Gastroesophageal Reflux
Study on Hydrotalcite for Relief of Acid Symptoms Due to Acid Rebound After Stopping Long-Term PPI Therapy
This observational study aims to explore the effectiveness of hydrotalcite, marketed as Talcid, in alleviating acid-related symptoms that occur due to an acid rebound after discontinuing a non-/no-longer-indicated long-term…
- Trial name
- NCT07291700
- Testing
- Hydrotalcite (Talcid, BAYX002833)
- Where
- 2 sites in Germany
- Volunteers
- 167 people
- Sponsor
- Bayer
No Condition
CLAiR Pivotal Study
This is a multi-site, observational clinical study to validate the performance of the CLAiR AI software in identifying elevated atherosclerotic cardiovascular disease (ASCVD) risk from retinal (eye) images obtained from two…
- Trial name
- NCT06808334
- Testing
- CLAIR
- Where
- United States
- Volunteers
- 942 people, healthy volunteers welcome
- Sponsor
- Toku Eyes Ltd
Chronic Hepatitis C
Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy
This Phase 3 clinical study is designed to evaluate the safety, tolerability, and efficacy of two dose levels of Infergen (interferon alfacon-1, CIFN) plus Ribavirin administered daily for 48 weeks and no treatment in patients…
- Trial name
- NCT00086541
- Testing
- Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks
- Volunteers
- 515 people
- Sponsor
- Bausch Health Americas, Inc.
no Specific Condition Targeted
Assessment of the Benefit of the Mobility Assistance System (SAM) on Transfer Independence for a Reimbursement Request
This is a randomized, cross-over, multi-center, intention-to-treat, open-label study to assess the impact of the SAM Ergonom light (SAM) device on independence when transferring from the supine to the sitting position at the edge…
- Trial name
- SAM-24 (NCT06698653)
- Testing
- SAM device (experimental): a removable structure, fixed to the horizontal frame of the medical bed, equipped with a handle to assist the sitting-up process, Over bed pole hoist (control device)
- Where
- 3 sites in France
- Volunteers
- 54 people
- Sponsor
- WINNCARE